SBIR/STTR Research Award
Amplification-free megabase target-enrichment for next-generation sequencing
Award amount
$215,000Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MISSION BIO INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- FCSLNELT6DG7
- Solicitation number
- PA13-235
- Topic code
- NHGRI
Research abstract
DESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target sequence enrichment. This technology is highly differentiated from all other enrichment approaches currently on themarket. Our method, MESA (Megabase Enrichment Sans Amplification), isolates large megabase-sized genomic DNA molecules in microfluidic drops and performs TaqMan PCR reactions to confirm the presence of the desired target sequence. The TaqMan identified drops are then sorted and collected to enrich for the target sequence prior to DNA sequencing. This approach is unique in that it is the only method that isolates intact megabase-sized fragments and does so without amplification of the DNA. The TaqMan P
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Measureable Residual Disease testing for acute myeloid leukemia with single-cell genotyping
- A robust platform for high throughput single cell genetic variation analysis
- SBIR Phase II: Low-cost Detection and Enrichment of Nucleic Acids by Interfacing with Commercially Available Cell Sorters
- Massively parallel quantitative single-cell PCR with qCell Arrays
- Molecular characterization of circulating tumor cells with PCR-activated cell sorting
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform to support clinical variant interpretation through probabilistic assessment of functional evidence
- Innovations to expand and accelerate the commercial impact of DNA modifications
- High-throughput Direct Sequencing and Quantitative Mapping of RNA Modifications using Mass Spectrometry.
- Super-resolution single-molecule sequencing by observing the dynamic hybridization of a repertoire of oligonucleotides to DNA targets
- Exhaustive de novo sequencing of every RNA in a sample by a layer-by-layer mass spectrometry ladder intensity approach.
Research funding history
9 SBIR/STTR records share this UEI (2014–2019). Reported award amounts total $5,783,511. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Health and Human Services, National Science Foundation